Genistein and daidzein modulate in vitro rat uterine contractile activity.
The present study investigated the effect of genistein, daidzein and estradiol on in vitro rat uterine responsiveness to oxytocin (OT) and PGF(2)alpha or luprostiol (L). In a first experiment, animals were either sham-operated (SH; n=5), or ovariectomized (OVX; n=20) and orally treated for three months with either genistein (G; n=5; 10 microg/g BW/d) or daidzein (D; n=5; 10 microg/g BW/d) or 17 alpha-ethinylestradiol (E; n=5; 23 microg/kg BW/d) or untreated (OVX; n=5). At necropsy, the basal uterine tension was lower in OVX, G and D than in SH, the highest value being measured in E. Oxytocin (10(-12); 10(-11) M) or PGF(2)alpha (10(-12); 10(-9) M) induced an increase in SH, but not in OVX, E and G. In D, only the highest doses were efficient. In a second experiment, 20 intact animals were s.c. injected with either genistein (G; n=5; 10 microg/g BW) or daidzein (D; n=5; 10 microg/g BW) or estradiol benzoate (E; n=5; 23 microg/kg BW) or vehicle (C: controls; n=5), and killed 24 h later. In C and E, OT (10(-15) to 10(-10) M) or L (10(-12) to 10(-7) M) stimulated uterine contractile activity in a dose-dependent manner until a maximal level. On the opposite, in G and D, contractile agents (except the highest luprostiol doses) did not stimulate myometrium contractions. Moreover, radioligand binding assays showed that genistein or daidzein inhibited the specific binding of [(3)H] estradiol to the calf uterus estrogen receptor (ER). Therefore, it could be postulated that both genistein and daidzein might bind to the rat uterus ER, inducing either anti-estrogenic or very weak estrogenic effects (depending on the experimental conditions) on in vitro uterine responsiveness to OT and PGF(2)alpha or luprostiol.
Picherit
C
C
Métabolisme Minéral, Laboratoire des Maladies Métaboliques et Micronutriments, I.N.R.A. Clermont-Ferrand/Theix, 63122 Saint Genès Champanelle, France.
Dalle
M
M
Néliat
G
G
Lebecque
P
P
Davicco
M J
MJ
Barlet
J P
JP
Coxam
V
V
D000818:Animals; D015237:Dinoprost / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology*; D009929:Organ Size; D010052:Ovariectomy; D010120:Oxytocics / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000378:metabolism; D014590:Uterine Contraction / Q000187:drug effects*; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology
D004791:Enzyme Inhibitors; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D010120:Oxytocics; D011461:Prostaglandins F, Synthetic; D011960:Receptors, Estrogen; C074283:estradiol 3-benzoate; D004958:Estradiol; D010121:Oxytocin; C004742:daidzein; D015237:Dinoprost; D019833:Genistein; C049643:luprostenol